File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The spike protein of SARS-CoV - A target for vaccine and therapeutic development

TitleThe spike protein of SARS-CoV - A target for vaccine and therapeutic development
Authors
Issue Date2009
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/nrmicro/
Citation
Nature Reviews Microbiology, 2009, v. 7 n. 3, p. 226-236 How to Cite?
AbstractSevere acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. In this Review, we highlight recent advances in the development of vaccines and therapeutics based on the S protein.
Persistent Identifierhttp://hdl.handle.net/10722/157540
ISSN
2015 Impact Factor: 24.727
2015 SCImago Journal Rankings: 16.373
ISI Accession Number ID
Funding AgencyGrant Number
National Institutes of Health (NIH)RO1 AI68002
Research Fund for the Control of Infectious Diseases
Food and Health Bureau of the Hong Kong SAR Government
National 973 Basic Research Program of China2005CB523001
Funding Information:

We thank all three anonymous reviewers for their constructive comments and informative suggestions. Our research was supported by the National Institutes of Health (NIH) of the United States (RO1 AI68002), by the Research Fund for the Control of Infectious Diseases, the Food and Health Bureau of the Hong Kong SAR Government, and by the National 973 Basic Research Program of China (2005CB523001).

References

 

DC FieldValueLanguage
dc.contributor.authorDu, Len_US
dc.contributor.authorHe, Yen_US
dc.contributor.authorZhou, Yen_US
dc.contributor.authorLiu, Sen_US
dc.contributor.authorZheng, BJen_US
dc.contributor.authorJiang, Sen_US
dc.date.accessioned2012-08-08T08:51:05Z-
dc.date.available2012-08-08T08:51:05Z-
dc.date.issued2009en_US
dc.identifier.citationNature Reviews Microbiology, 2009, v. 7 n. 3, p. 226-236en_US
dc.identifier.issn1740-1526en_US
dc.identifier.urihttp://hdl.handle.net/10722/157540-
dc.description.abstractSevere acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. In this Review, we highlight recent advances in the development of vaccines and therapeutics based on the S protein.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/nrmicro/en_US
dc.relation.ispartofNature Reviews Microbiologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Monoclonal - Immunology - Therapeutic Useen_US
dc.subject.meshAntiviral Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMembrane Glycoproteins - Chemistry - Immunology - Physiologyen_US
dc.subject.meshPeptidyl-Dipeptidase A - Metabolismen_US
dc.subject.meshRna Interferenceen_US
dc.subject.meshRna, Small Interferingen_US
dc.subject.meshSars Virus - Chemistry - Drug Effects - Genetics - Physiologyen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Pathology - Prevention & Control - Therapyen_US
dc.subject.meshViral Envelope Proteins - Chemistry - Immunology - Physiologyen_US
dc.subject.meshViral Vaccines - Immunologyen_US
dc.subject.meshVirus Internalizationen_US
dc.titleThe spike protein of SARS-CoV - A target for vaccine and therapeutic developmenten_US
dc.typeArticleen_US
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_US
dc.identifier.authorityZheng, BJ=rp00353en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/nrmicro2090en_US
dc.identifier.pmid19198616en_US
dc.identifier.scopuseid_2-s2.0-60749134643en_US
dc.identifier.hkuros156487-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-60749134643&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume7en_US
dc.identifier.issue3en_US
dc.identifier.spage226en_US
dc.identifier.epage236en_US
dc.identifier.isiWOS:000263361000014-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridDu, L=8686996200en_US
dc.identifier.scopusauthoridHe, Y=8742157400en_US
dc.identifier.scopusauthoridZhou, Y=8791655300en_US
dc.identifier.scopusauthoridLiu, S=8287444600en_US
dc.identifier.scopusauthoridZheng, BJ=7201780588en_US
dc.identifier.scopusauthoridJiang, S=7404453146en_US
dc.identifier.citeulike4063588-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats